Safety and immunogenicity of COVID-19 peptide vaccine

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge worldwide. South America is struggling with the Gamma variant, while the Delta variant is the cause of most new infections across the U.S. and Europe. These variants have repeatedly shown the ability to evade both vaccine-induced and natural immunity. The rising case numbers in Europe have even forced some countries back into costly and restrictive lockdowns.

Study: A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Image Credit: Corona Borealis Studio/Shutterstock

In a study published in Nature, researchers from University Hospital Tübingen have been investigating the results from a Phase I trial for a new vaccine against SARS-CoV-2 variants.

The study


Continue Reading

News Source: